Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Preety RawalDinesh Mani TripathiHamed HematiJitendra KumarPurnima TyagiShiv Kumar SarinVikrant NainSavneet KaurPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
Thus, targeting of HBx by CRISPR/Cas9 gene editing system reduces covalently closed circular DNA (cccDNA) levels, HBsAg production and mesenchymal characteristics of HBV-HCC cells. We envision inhibition of HBx by CRISPR as a novel therapeutic approach for HBV-induced HCC.